| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9375478 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9744209 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9937223 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9744239 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US10010575 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9981006 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9974827 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9968649 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9962422 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9925234 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9925233 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9687526 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9750785 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
| US9919026 | PAR STERILE PRODUCTS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(11 years from now) | |
Vasostrict is owned by Par Sterile Products.
Vasostrict contains Vasopressin.
Vasostrict has a total of 14 drug patents out of which 0 drug patents have expired.
Vasostrict was authorised for market use on 17 April, 2014.
Vasostrict is available in solution;intravenous dosage forms.
Vasostrict can be used as to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
The generics of Vasostrict are possible to be released after 30 January, 2035.
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines
Dosage: SOLUTION;INTRAVENOUS
VASOSTRICT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic